IPQ Inside the global regulatory dialogue

Communication Between CMC and Clinical Groups is Key in IND Phase, FDA says

Jul 15th, 2010

Please Log in to print the full article

FDA Center for Drug Evaluation and Research (CDER) is stressing that communication problems between the CMC and clinical groups working in Phase I can result in important risks not being identified and can impede IND/Phase...

You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.

©2021 IPQ Publications